Cytomegalovirus disease in adult marrow transplant recipients receiving ganciclovir prophylaxis: a retrospective study
Autor: | H, Maltezou, E, Whimbey, D, Abi-Said, D, Przepiorka, R, Champlin, J, Goodrich, H, Maltazou, R, Champlain |
---|---|
Rok vydání: | 1999 |
Předmět: |
Ganciclovir
Human cytomegalovirus Adult Male medicine.medical_specialty Adolescent viruses medicine.medical_treatment Congenital cytomegalovirus infection Antiviral Agents Lymphocyte Depletion Betaherpesvirinae Risk Factors Internal medicine medicine Humans Bone Marrow Transplantation Retrospective Studies Transplantation Chemotherapy biology business.industry virus diseases Retrospective cohort study Hematology Middle Aged medicine.disease biology.organism_classification humanities Tacrolimus Surgery body regions Survival Rate surgical procedures operative medicine.anatomical_structure Cytomegalovirus Infections Female Bone marrow business medicine.drug |
Zdroj: | Bone marrow transplantation. 24(6) |
ISSN: | 0268-3369 |
Popis: | In a retrospective study, we compared the incidence and risk of mortality associated with CMV disease in adult allogeneic BMT and PBSC recipients who received ganciclovir prophylaxis three-times-per-week (78 patients) vs five-times-per-week (137 patients). Active CMV infection occurred in 28 (41%) and 26 (21%) in the three- vs five-times-per-week groups, respectively (P0.005). CMV disease developed in 11 (16%) and five (4%) patients who received ganciclovir prophylaxis in the three-times-per-week vs five-times-per-week groups (P0.004). The CMV-attributable mortality rate was 1.5% and 12% in the five- vsthree-times-per-week groups, respectively (P0.003). Risk factors for CMV disease, significant at the P0.05 level in the multivariate analysis, were ganciclovir prophylaxis at three-times-per-week, receiving a T cell-depleted (TCD) marrow, and tacrolimus as prophylaxis for GVHD. These data suggest that ganciclovir five-times-per-week significantly reduced the incidence and mortality of CMV disease in allogeneic BMT and PBSC recipients. However, ganciclovir five-times-per-week was less effective for the prevention of CMV disease in patients receiving TCD marrow or tacrolimus. |
Databáze: | OpenAIRE |
Externí odkaz: |